| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/08/2004 | WO2002072796A3 Continuous, normal human t-lymphocyte cell lines comprising a recombinant immune receptor with defined antigen specificity |
| 01/08/2004 | WO2002072780A3 Igf antagonist peptides |
| 01/08/2004 | WO2002066053A3 Method of treating or preventing disease characterized by cryptococcus neoformans infection |
| 01/08/2004 | WO2002053596A3 Antibodies to insulin-like growth factor i receptor |
| 01/08/2004 | WO2002046225A3 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 01/08/2004 | WO2002045743A3 Hcv vaccines |
| 01/08/2004 | WO2002045737A3 Methods of treatment involving human mda-7 |
| 01/08/2004 | US20040006780 VEGF-modulated genes and methods employing them |
| 01/08/2004 | US20040006242 Immunomodulatory compounds and method of use thereof |
| 01/08/2004 | US20040006218 Comprises nucleotide sequences coding microorganismal envelop proteins for vaccine development, diagnosis and infection prevention; immunotherapy; bactericides |
| 01/08/2004 | US20040006216 Comprises immunoglobulin for treating cancer; immunosuppressant; immunotherapy |
| 01/08/2004 | US20040006215 Human monoclonal antibodies against CD30 |
| 01/08/2004 | US20040006209 Comprises immunoglobulin which specifically binds staphylococcal g-protein and receptor sites for preventing and treating infections; gentic vaccines |
| 01/08/2004 | US20040006208 Comprises three-dimensional structure of bound immunoglobulin complex; antiinflammatory/anticarcinogenic; viricides |
| 01/08/2004 | US20040006207 Comprises ligand polypeptide for treatment of viral infection and prevention of immunological response; immunosuppressants; genetic vaccines |
| 01/08/2004 | US20040006204 Preparing amino acid sequences associated with fatty acid binding proteins (FABP); mimetics; parasitides; genetic vaccines for preventing schiostosoma and/or fasciola infections; veterinary medicines |
| 01/08/2004 | US20040006087 Method of treating cancer using FPT inhibitors and antineoplastic agents |
| 01/08/2004 | US20040006037 Flagellin gene, flaC of Campylobacter |
| 01/08/2004 | US20040006034 Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| 01/08/2004 | US20040006032 Vaccination |
| 01/08/2004 | US20040006028 Administering a therapeutically effective amount of a flavin N-oxide; exposing flavin N-oxide to an activator, such that activation of the flavin N- oxide results in damage to the DNA in cancer cells without damage to the DNA in normal cells |
| 01/08/2004 | US20040006022 For therapy of autoimmune or an inflammatory disease |
| 01/08/2004 | US20040006010 Compositions include a polynucleotide that is linked to an immunomodulatory molecule, which molecule comprises an antigen and may further comprise immunomodulators such as cytokines and adjuvants. The polynucleotide portion of the |
| 01/08/2004 | US20040006004 This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 |
| 01/08/2004 | US20040006001 Ferritin fusion proteins for use in vaccines and other applications |
| 01/08/2004 | US20040005998 Producing large lots of final sterile Poly-ICLC suitable for clinical use with reduced toxicity at effective dose levels, and method for using Poly-ICLC to regulate genes, and method for using Poly-ICLC to treat certain human and veterinary |
| 01/08/2004 | US20040005996 Method of producing protein stabilised emulsions comprising the steps of decreasing the pH of a protein solution by the addition of an acidic solution to convert it to a cationic form, heating the solution until the protein is solubilised, |
| 01/08/2004 | US20040005712 Transforming B lymphocytes with Epstein-Barr virus, incubating transformed B lymphocytes with flavin N-oxide photosensitizer, adding non-toxic antioxidant, and exposing lymphocytes to activator such as photoradiation to activate photosensitizer |
| 01/08/2004 | US20040005711 Alphaviral vector system comprising papilloma viral orgin of replication and antitumor agent for prevention and treatment urogenital cancer; gene therapy |
| 01/08/2004 | US20040005693 Propagating and extracting reovirus from human embryonic kidney cells; ion exchange chromatography |
| 01/08/2004 | US20040005688 Comprises dishevelled associated kinase (DAK) protein for diagnosis, prevention and treatment of cell proliferative diseases |
| 01/08/2004 | US20040005671 Immunointeractive molecules |
| 01/08/2004 | US20040005667 Comprises protein for developing vaccines which prevent chlamydial infections; genetic vaccines |
| 01/08/2004 | US20040005662 Culuring transgenic cells which codes bactericides; genetic vaccines |
| 01/08/2004 | US20040005654 Method of producing polyvalent antigens |
| 01/08/2004 | US20040005643 Anti-human tenascin monoclonal antibody |
| 01/08/2004 | US20040005642 Comprises expression vectors coding antiproliferative agents; antisense agents; tumor diagnosis and treatment |
| 01/08/2004 | US20040005630 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| 01/08/2004 | US20040005629 Natural ligand of orphan G protein coupled receptor GPR86 and methods of use |
| 01/08/2004 | US20040005626 Comprises nucleotide sequences coding membrane protein for diagnosing and treating inflammatory and tumor disorders |
| 01/08/2004 | US20040005600 Designing expression vector for improved accumulation of plasmodium protein in transformed cells |
| 01/08/2004 | US20040005598 Comprises nucleotide sequences coding protein upregulated in metastatic prostate cancer (PUMPCn) for diagnosis and treatment of tumors; antiproliferative agents; anticarcinogenic agents |
| 01/08/2004 | US20040005592 Materials and methods relating to therapy and diagnosis using targeting of cells that express DCAL-Hy polypeptides |
| 01/08/2004 | US20040005588 Using DNA vaccines to treat and prevent insulin depentent diabetes mellitus |
| 01/08/2004 | US20040005576 Comprises polypeptides for diagnosing, prognosing and preventing cancer, nervous system, developmental and metabolic disorders |
| 01/08/2004 | US20040005561 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 01/08/2004 | US20040005550 Methods and compositions useful for targeting activated vitronectin receptor alphavbeta3 |
| 01/08/2004 | US20040005545 Plasmid comprising heterologous viral gene sequences for diagnosis, prevention and treatment of respiratory system disorders; vaccine development; viricides |
| 01/08/2004 | US20040005544 Comprise RNA viruses for diagnosis, prevention and treatment of repiratory system disorders; vaccine development; viricides; antisense therapy |
| 01/08/2004 | US20040005338 Virus like particles (VLPs) can be loaded and packaged, respectively, with DNA oligonucleotides rich in non-methylated C and G (CpGs). If such CpG-VLPs are mixed with antigens, the immunogenicity of these antigens are |
| 01/08/2004 | US20040005332 Application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native |
| 01/08/2004 | US20040005331 Polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for |
| 01/08/2004 | US20040005330 Mutated HIV Tat |
| 01/08/2004 | US20040005328 Novel antigens of B. catarrhalis are provided, together with their use in vaccines as well as methods of diagnosing and/or detection. Branhamella catarrhalis (also known as Moraxella catarrhalis) is a gram-negative aerobic bacterium that causes |
| 01/08/2004 | US20040005326 Leishmania vaccine |
| 01/08/2004 | US20040005325 Helicobacter felis vaccine |
| 01/08/2004 | US20040005324 Identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies |
| 01/08/2004 | US20040005323 Efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro primary of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human |
| 01/08/2004 | US20040005322 Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| 01/08/2004 | US20040005321 Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotheraphy |
| 01/08/2004 | US20040005318 Method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided. |
| 01/08/2004 | US20040005316 Use of HMG fragments as anti-inflammatory agents |
| 01/08/2004 | US20040005315 Administering an immunosuppressive agent that depletes T cells and anti-alpha beta T cell receptor antibodies, and implanting an allograft into the recipient. |
| 01/08/2004 | US20040005314 Apo-2l receptor agonist and cpt-11 synergism |
| 01/08/2004 | US20040005313 Use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| 01/08/2004 | US20040005307 Modulators of amyloid aggregation |
| 01/08/2004 | US20040005302 Use of immunoisolating implantable devices enclosing genetically engineered antigen-producing cells for eliciting immune responses against an antigen in a host. |
| 01/08/2004 | US20040005300 By transplanting with hematopoietic stem cells from a donor that are matched at the major histocompatibility complex class I K locus with the recipient hematopoietic microenvironment. |
| 01/08/2004 | US20040005276 Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with porphyromonas gingivalis |
| 01/08/2004 | CA2844639A1 Method for the treatment of multiple sclerosis |
| 01/08/2004 | CA2492135A1 Medicament for the treatment of diseases due to infection by neisseria meningitidis |
| 01/08/2004 | CA2492131A1 Live replicating spumavirus vector |
| 01/08/2004 | CA2492057A1 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| 01/08/2004 | CA2491540A1 Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders |
| 01/08/2004 | CA2491480A1 Humanized anti-lymphotoxin beta receptor antibodies |
| 01/08/2004 | CA2491427A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | CA2491363A1 Antibodies and uses thereof |
| 01/08/2004 | CA2491053A1 Use of antibodies against flt-1 for the treatment of osteoporosis |
| 01/08/2004 | CA2490885A1 Avian cytokines, such as il-12, comprising a p40 and/or p35 subunit(s) |
| 01/08/2004 | CA2490866A1 Viruses and virus-like particles for multiple antigen and target display |
| 01/08/2004 | CA2490863A1 Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase |
| 01/08/2004 | CA2490804A1 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| 01/08/2004 | CA2490411A1 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | CA2490283A1 Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance |
| 01/08/2004 | CA2490280A1 Antibodies that specifically bind to reg iv |
| 01/08/2004 | CA2490186A1 Method for the treatment of multiple sclerosis |
| 01/08/2004 | CA2489515A1 Methods and compositions for modulating and detecting wisp activity |
| 01/08/2004 | CA2487712A1 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 01/07/2004 | EP1378570A1 Flk-1 is a receptor for vascular endothelial growth factor |
| 01/07/2004 | EP1378525A2 Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods |
| 01/07/2004 | EP1378524A2 Recombinant thrombin receptor antibodies and their use |
| 01/07/2004 | EP1378520A1 Cyclic single strand trispecific antibody |
| 01/07/2004 | EP1378516A1 Mixture of recombinant vaccinia vectors as polyenv vaccines for HIV |
| 01/07/2004 | EP1378245A2 Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis. Their use in a vaccine |
| 01/07/2004 | EP1378241A1 Pharmaceutical compositions comprising arsenic for the treatment of melanoma |
| 01/07/2004 | EP1378240A2 Pharmaceutical compositions comprising arsenic for the treatment of multiple myeloma |
| 01/07/2004 | EP1377833A2 Gastrointestinal glutathione peroxidase in hepatitis c virus infections |
| 01/07/2004 | EP1377668A2 Artificial chromosomes comprising ehv sequences |
| 01/07/2004 | EP1377660A2 Vaccine against the nile fever virus |
| 01/07/2004 | EP1377611A2 Muteins of hypoxia inducible factor alpha and methods of use thereof |